Endo International (ENDP) Gains on Acerus Deal

Endo International plc ENDP shares hiked 2.5% to $16.94, on word Acerus Pharmaceuticals completed the NATESTO® U.S. transition from an affiliate of Endo back to Acerus, and subsequently to Aytu BioScience, Inc. Aytu will now assume responsibility for the U.S. commercialization of NATESTO®, the first and only FDA-approved testosterone nasal gel indicated for replacement therapy in adult males diagnosed with hypogonadism. Share volume was five million, compared to an all-day average of 10 million